Cancer
Oesophageal squamous cell carcinoma in Anyang
安阳 食管鳞状细胞癌
1 hospital in Anyang
Order: papers led on oesophageal squamous cell carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for oesophageal squamous cell carcinoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Anyang may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 17 papers ledNo open trial led
Oesophageal squamous cell carcinoma in every city Anyang on the disease page, with the national map
open trials on oesophageal squamous cell carcinoma with a hospital in Anyang
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with a listed hospital in Anyang as lead sponsor or study site. 0 of them are led by a hospital in Anyang. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06342167
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan
- RecruitingInduction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
- Phase
- Phase 2
- Started
- 2024-05
- Registry
- NCT06421376
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang
- RecruitingChemoradiotherapy in Unresectable Esophageal Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-10
- Registry
- NCT04278287
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing
- RecruitingChemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
- Phase
- N/A
- Started
- 2016-11
- Registry
- NCT02972372
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Anyang
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Anyang Tumor Hospital安阳市肿瘤医院 | none | 17 | none | 10 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Anyang.
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for oesophageal squamous cell carcinoma.
Counts are listed hospitals only, not every hospital in each city.
- 57 kmHandan邯郸None listed for oesophageal squamous cell carcinoma
- 98 kmXinxiang新乡2 hospitals for oesophageal squamous cell carcinoma
- 106 kmXingtai邢台None listed for oesophageal squamous cell carcinoma
- 113 kmChangzhi长治1 hospital for oesophageal squamous cell carcinoma
- 141 kmJiaozuoNone listed for oesophageal squamous cell carcinoma
- 145 kmKaifeng开封1 hospital for oesophageal squamous cell carcinoma
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Anyang on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.